イタバシ　ミチオ   Itabashi Michio   板橋　道朗    所属   医学部 医学科    職種   特任教授
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.
掲載誌名	正式名：International journal of clinical oncology 略　 称：Int J Clin Oncol ISSNコード：14377772/13419625
掲載区分	国外
巻・号・頁	26(8),pp.1353-1419
著者・共著者	Tomita Naohiro, Ishida Hideyuki, Tanakaya Kohji, Yamaguchi Tatsuro, Kumamoto Kensuke, Tanaka Toshiaki, Hinoi Takao, Miyakura Yasuyuki, Hasegawa Hirotoshi, Takayama Tetsuji, Ishikawa Hideki, Nakajima Takeshi, Chino Akiko, Shimodaira Hideki, Hirasawa Akira, Nakayama Yoshiko, Sekine Shigeki, Tamura Kazuo, Akagi Kiwamu, Kawasaki Yuko, Kobayashi Hirotoshi, Arai Masami, Itabashi Michio, Hashiguchi Yojiro, Sugihara Kenichi,
発行年月	2021/08
概要	Hereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics necessitate different management approaches, including diagnosis, treatment or surveillance, from sporadic colorectal cancer management. There are two representative HCRC, named familial adenomatous polyposis and Lynch syndrome. Other than these two HCRC syndromes, related disorders have also been reported. Several guidelines for hereditary disorders have already been published worldwide. In Japan, the first guideline for HCRC was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016. This revised version of the guideline was immediately translated into English and published in 2017. Since then, several new findings and novel disease concepts related to HCRC have been discovered. The currently diagnosed HCRC rate in daily clinical practice is relatively low; however, this is predicted to increase in the era of cancer genomic medicine, with the advancement of cancer multi-gene panel testing or whole genome testing, among others. Under these circumstances, the JSCCR guidelines 2020 for HCRC were prepared by consensus among members of the JSCCR HCRC Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR guidelines 2020 for HCRC.
DOI	10.1007/s10147-021-01881-4
PMID	34185173